Screener
IDEAYA Biosciences, Inc. IDYA Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by IDEAYA Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206357
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation and amortization | 688 | 600 |
| Net accretion of discounts on marketable securities | (1,211) | (3,778) |
| Stock-based compensation | 14,536 | 10,237 |
| Amortization of right-of-use assets | 455 | 533 |
| Changes in assets and liabilities | ||
| Prepaid expenses and other assets | 3,025 | (1,970) |
| Accounts payable | 3,050 | 2,728 |
Item 1. Financial Statements (UNAUDITED).
FAQ
- What is IDEAYA Biosciences, Inc.'s stock-based comp?
- IDEAYA Biosciences, Inc. (IDYA) reported stock-based comp of $14.54M in Q1 2026.
- How has IDEAYA Biosciences, Inc.'s stock-based comp changed year-over-year?
- IDEAYA Biosciences, Inc.'s stock-based comp increased by 42.0% year-over-year, from $10.24M to $14.54M.
- What is the long-term trend for IDEAYA Biosciences, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), IDEAYA Biosciences, Inc.'s stock-based comp has grown at a 53.8% compound annual growth rate (CAGR), from $8.24M to $46.12M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about IDEAYA Biosciences, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude